NASDAQ:VINC Vincerx Pharma - VINC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.31 0.00 (0.00%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.31▼$1.4050-Day Range$0.64▼$1.5152-Week Range$0.63▼$7.14Volume26,202 shsAverage Volume100,213 shsMarket Capitalization$27.76 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vincerx Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside666.3% Upside$10.00 Price TargetShort InterestHealthy3.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$55,983 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.89) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.62 out of 5 starsMedical Sector83rd out of 1,027 stocksPharmaceutical Preparations Industry31st out of 500 stocks 3.5 Analyst's Opinion Consensus RatingVincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Vincerx Pharma has a forecasted upside of 666.3% from its current price of $1.31.Amount of Analyst CoverageVincerx Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.63% of the float of Vincerx Pharma has been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vincerx Pharma has recently decreased by 12.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVincerx Pharma does not currently pay a dividend.Dividend GrowthVincerx Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VINC. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Vincerx Pharma this week, compared to 0 articles on an average week.Search InterestOnly 6 people have searched for VINC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vincerx Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,983.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders23.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.55% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Vincerx Pharma are expected to grow in the coming year, from ($2.89) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vincerx Pharma is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vincerx Pharma is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVincerx Pharma has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vincerx Pharma (NASDAQ:VINC) StockVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.Read More Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VINC Stock News HeadlinesFebruary 6, 2023 | finance.yahoo.comVincerx Pharma to Participate at the SVB Securities Global Biopharma ConferenceDecember 15, 2022 | msn.comPeering Into Vincerx Pharma's Recent Short InterestFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 13, 2022 | finance.yahoo.comVincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236December 11, 2022 | finance.yahoo.comVincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022November 10, 2022 | finance.yahoo.comVincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateNovember 3, 2022 | finance.yahoo.comVincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022September 22, 2022 | nasdaq.comHere's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash WiselyFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...September 20, 2022 | finance.yahoo.comVincerx Pharma, Inc. (VINC)August 12, 2022 | markets.businessinsider.com5 Analysts Have This to Say About Vincerx PharmaAugust 11, 2022 | finance.yahoo.comWe Think Vincerx Pharma (NASDAQ:VINC) Needs To Drive Business Growth CarefullyAugust 11, 2022 | finance.yahoo.comVincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateJuly 1, 2022 | finance.yahoo.comInsider Buying: The Vincerx Pharma, Inc. (NASDAQ:VINC) Founder Just Bought 2.5% More SharesJune 10, 2022 | finance.yahoo.comVincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 CongressJune 7, 2022 | finance.yahoo.comAnalysts Cuts Price Target On This Small Cap But Remain BullishJune 7, 2022 | markets.businessinsider.com7 Analysts Have This to Say About Vincerx PharmaJune 7, 2022 | finance.yahoo.comSmall Cap Biotech Vincerx Cuts Third Of StaffJune 6, 2022 | seekingalpha.comVincerx Pharma to cut workforce by 33%, prioritize resources on ongoing trialsJune 6, 2022 | finance.yahoo.comVincerx Pharma Provides Key Strategic UpdateJune 6, 2022 | finance.yahoo.comVincerx Pharma, Inc. (NASDAQ:VINC) up 10%, but insiders are still down 85% after purchasing US$806k of stock last yearMay 25, 2022 | uk.investing.comStocks That Hit 52-Week Lows On Tuesday By Benzinga - Investing.com UKMay 19, 2022 | nasdaq.comBuying Power of Bitcoin vs. Vincerx Pharma at New 52-Week HighMay 13, 2022 | benzinga.comChardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $11 - Benzinga - BenzingaMay 13, 2022 | globenewswire.comVincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update - GlobeNewswireApril 11, 2022 | finance.yahoo.comVincerx Pharma Highlights VIP152 Preclinical, Clinical Data In Gynecological CancersMarch 30, 2022 | seekingalpha.comVincerx Pharma GAAP EPS of -$0.31See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VINC Company Calendar Last Earnings11/10/2022Today2/06/2023Next Earnings (Estimated)4/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VINC CUSIPN/A CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$28.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+663.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-85.86% Return on Assets-72.79% Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio6.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.76 per share Price / Book0.28Miscellaneous Outstanding Shares21,190,000Free Float16,189,000Market Cap$27.76 million OptionableNot Optionable Beta0.48 Key ExecutivesDr. Ahmed M. Hamdy M.D. (Age 57)Founder, Chairman & CEO Comp: $614.91kMr. Tom C. Thomas J.D. (Age 63)Founder, Gen. Counsel & Chief Legal Officer Comp: $444.14kDr. Raquel E. Izumi Ph.D. (Age 52)Founder, Pres, COO, Sec. & Director Dr. John C. Byrd M.D.Founder & Chairman of Scientific Advisory BoardMr. Alexander A. Seelenberger M.B.A. (Age 43)MBA, Chief Financial Officer Dr. Hans-Georg Lerchen Ph.D.Chief Scientific OfficerMs. Melissa Merrick SPHRSr. Director of People & CultureDr. David Nganele M.B.A.Ph.D., Head of Early Devel.Dr. Beatrix Stelte-Ludwig Ph.D.Exec. Chief Devel. OfficerMore ExecutivesKey CompetitorsAdamis PharmaceuticalsNASDAQ:ADMPTFF PharmaceuticalsNASDAQ:TFFPFlora GrowthNASDAQ:FLGCSio Gene TherapiesNASDAQ:SIOXMolecular TemplatesNASDAQ:MTEMView All CompetitorsInsiders & InstitutionsSage Rhino Capital LLCBought 28,738 shares on 2/1/2023Ownership: 7.961%Ahmed Md HamdyBought 35,280 shares on 12/14/2022Total: $30,693.60 ($0.87/share)Raquel E IzumiBought 28,738 shares on 12/14/2022Total: $25,289.44 ($0.88/share)Long Focus Capital Management LLCBought 81,505 shares on 11/15/2022Ownership: 5.009%Vanguard Group Inc.Sold 57,269 shares on 11/15/2022Ownership: 2.464%View All Insider TransactionsView All Institutional Transactions VINC Stock - Frequently Asked Questions Should I buy or sell Vincerx Pharma stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VINC shares. View VINC analyst ratings or view top-rated stocks. What is Vincerx Pharma's stock price forecast for 2023? 5 Wall Street research analysts have issued twelve-month target prices for Vincerx Pharma's stock. Their VINC share price forecasts range from $3.00 to $28.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 663.4% from the stock's current price. View analysts price targets for VINC or view top-rated stocks among Wall Street analysts. How have VINC shares performed in 2023? Vincerx Pharma's stock was trading at $1.02 at the start of the year. Since then, VINC shares have increased by 28.4% and is now trading at $1.31. View the best growth stocks for 2023 here. When is Vincerx Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. View our VINC earnings forecast. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) issued its quarterly earnings data on Thursday, November, 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.80). What is Vincerx Pharma's stock symbol? Vincerx Pharma trades on the NASDAQ under the ticker symbol "VINC." Who are Vincerx Pharma's major shareholders? Vincerx Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Sage Rhino Capital LLC (7.96%). Insiders that own company stock include Ahmed Md Hamdy, Alexander A Seelenberger, Andrew I Mcdonald, Christopher P Lowe, Laura I Bushnell, Raquel E Izumi and Tom C Thomas. View institutional ownership trends. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vincerx Pharma's stock price today? One share of VINC stock can currently be purchased for approximately $1.31. How much money does Vincerx Pharma make? Vincerx Pharma (NASDAQ:VINC) has a market capitalization of $27.76 million. The company earns $-39,310,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. How can I contact Vincerx Pharma? Vincerx Pharma's mailing address is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. The official website for the company is vincerapharma.com. The company can be reached via phone at 650-800-6676. This page (NASDAQ:VINC) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.